In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Hold rating on Proteon (NASDAQ: PRTO). The company’s shares opened today at $2.10.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.3% and a 51.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Proteon has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Based on Proteon’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.08 million. In comparison, last year the company had a GAAP net loss of $6.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA.
